For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.

Use of the Palliative Performance Scale to estimate survival among home hospice patients with heart failure.

TitleUse of the Palliative Performance Scale to estimate survival among home hospice patients with heart failure.
Publication TypeJournal Article
Year of Publication2019
AuthorsCreber RMasterson, Russell D, Dooley F, Jordan L, Baik D, Goyal P, Hummel S, Hummel EK, Bowles KH
JournalESC Heart Fail
Volume6
Issue2
Pagination371-378
Date Published2019 Apr
ISSN2055-5822
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Heart Failure, Hospice Care, Humans, Male, Middle Aged, Palliative Care, Prognosis, Retrospective Studies, ROC Curve, Survival Rate, Time Factors, United States, Young Adult
Abstract

AIMS: Estimating survival is challenging in the terminal phase of advanced heart failure. Patients, families, and health-care organizations would benefit from more reliable prognostic tools. The Palliative Performance Scale Version 2 (PPSv2) is a reliable and validated tool used to measure functional performance; higher scores indicate higher functionality. It has been widely used to estimate survival in patients with cancer but rarely used in patients with heart failure. The aim of this study was to identify prognostic cut-points of the PPSv2 for predicting survival among patients with heart failure receiving home hospice care.

METHODS AND RESULTS: This retrospective cohort study included 1114 adult patients with a primary diagnosis of heart failure from a not-for-profit hospice agency between January 2013 and May 2017. The primary outcome was survival time. A Cox proportional-hazards model and sensitivity analyses were used to examine the association between PPSv2 scores and survival time, controlling for demographic and clinical variables. Receiver operating characteristic curves were plotted to quantify the diagnostic performance of PPSv2 scores by survival time. Lower PPSv2 scores on admission to hospice were associated with decreased median (interquartile range, IQR) survival time [PPSv2 10 = 2 IQR: 1-5 days; PPSv2 20 = 3 IQR: 2-8 days] IQR: 55-207. The discrimination of the PPSv2 at baseline for predicting death was highest at 7 days [area under the curve (AUC) = 0.802], followed by an AUC of 0.774 at 14 days, an AUC of 0.736 at 30 days, and an AUC of 0.705 at 90 days.

CONCLUSIONS: The PPSv2 tool can be used by health-care providers for prognostication of hospice-enrolled patients with heart failure who are at high risk of near-term death. It has the greatest utility in patients who have the most functional impairment.

DOI10.1002/ehf2.12398
Alternate JournalESC Heart Fail
PubMed ID30835970
PubMed Central IDPMC6437549
Grant ListR00 NR016275 / NR / NINR NIH HHS / United States
T32 NR007969 / NR / NINR NIH HHS / United States
T32NR007969 / NR / NINR NIH HHS / United States
R00NR016275 / NR / NINR NIH HHS / United States
Division: 
Health Informatics
Category: 
Faculty Publication